Hepatotoxicity Screen
Drug-induced liver injury (DILI) is one of the leading causes of late-stage clinical trial failure and post-market drug withdrawal. Traditional preclinical models often lack the complexity and human relevance needed to accurately predict hepatotoxic risks. At Greenstone Biosciences, our Hepatotoxicity Screen leverages iPSC-derived hepatocyte models to bring unprecedented accuracy and translational value to liver safety testing.
By using hepatocytes derived from human induced pluripotent stem cells, we replicate the key functional, metabolic, and genetic characteristics of the human liver. This allows us to detect acute, sub-chronic, and chronic hepatotoxicity while also revealing mechanistic insights into liver injury.
What the Hepatotoxicity Screen Provides
Why It Matters
By mimicking key aspects of human liver biology, our platform enables more reliable toxicity predictions than conventional in vitro or animal-based models. This reduces reliance on animal studies, accelerates decision-making, and enhances confidence in clinical translation.
De-Risking Development Pipelines
The Hepatotoxicity Screen empowers drug developers to proactively identify hepatotoxic risk, preventing costly failures in late-stage trials and reducing the chance of regulatory setbacks. With human-relevant data generated early in development, researchers can make smarter, evidence-driven decisions about which compounds to advance.
A Safer Path Forward
Our iPSC-based hepatotoxicity assays don’t just detect risk—they help define the underlying mechanisms, supporting a more informed, mechanistic approach to drug safety. By integrating predictive liver models into the discovery process, Greenstone Biosciences is helping shape a future where new therapies reach patients with greater safety and efficiency.